Healio Rheumatology Current Issue

The following articles appeared in the print edition of Healio Rheumatology.

Table of Contents

• Staying on Top of Vaccination Schedules in Patients With Rheumatologic Diseases
• FDA Approves Xeljanz for Adults With Psoriatic Arthritis
• FDA Accepts Application for New Humira Biosimilar
• FDA Approves Ixifi, Third Remicade Biosimilar
• FDA Expands Approval of Nucala for Eosinophilic Granulomatosis With Polyangiitis
• FDA Grants Fast Track Designation to CNTX-4975 Injection for Osteoarthritis Knee Pain
• FDA Resources Can Help Prescribers Better Understand Biosimilars
• FDA Denies Amneal Request to Block Approvals of Generic Forteo
• What Rheumatologists Need to Know in the Era of Herpes Zoster Prevention Leonard H. Calabrese, DO
• Ace the Case: A 24-Year-Old Female with Chronic Low-Back Stiffness
• ACR/EULAR Identify 40 Candidate Criteria for SLE Classification
• AECG, ACR/EULAR Classification Criteria for Sjögren’s Syndrome in ‘Excellent’ Agreement
• CreakyJoints Publishes First Patient-centered OA Guidelines
• EULAR Recommends Core Data Set to Enable Standardized, Collaborative RA Research
• Adalimumab Biosimilar Safe, Effective in RA
• ‘Creaky Knees’ Can Predict Symptomatic OA
• Glucocorticoid Benefits Outweighed Adverse Effects Among Patients With Rheumatic Conditions
• HBV Testing Rates Remain Low Among Patients With RA
• Opioid Use for Ankylosing Spondylitis More Likely Linked to Subjective Disease Measures
• Persistent Arthritis Reported in 25% of Patients After Chikungunya Infection
• Stem Cell Transplant Improves Overall, Event-free Survival in Scleroderma
• Total Joint Arthroplasty More Common in Ontario Than New York
• ACR President Discusses NIH Budget Cuts, Workforce Shortages, Untapped Potential for Rheumatologists
• Fitzgerald Resigns as CDC Director Over ‘Complex’ Financial Conflicts
• ACR Urges HHS to Reform Prior Authorization Policies
• New HHS Secretary Vows to ‘Bring Down Prescription Drug Prices’
• FDA Drug Approvals Hit 21-year High in 2017